Development of Glycosaminoglycan-Targeting Antibodies to Unravel ECM Remodeling in Atopic Diseases (A06)

• Subject Area: Organic Molecular Chemistry - Synthesis and Characterisation
• Term: since 2018
• Project identifier: Deutsche Forschungsgemeinschaft (DFG) - Project number 372486779

Many pathologies are characterized by changes in the amount, composition, and chemical structure of glycosaminoglycans (GAGs) and proteoglycans in the extracellular matrix (ECM). In this project, we leverage high-end imaging techniques to capture ECM-related changes in atopic dermatitis on three levels: in proteoglycans, the GAGs they carry, and/or their poorly understood S-domain patterns. We aim to improve our understanding of interconnections between inflammation and ECM-related GAGs and proteoglycans in atopic diseases yielding the identification of inflammation-related GAG/proteoglycan markers and/or ECM-related changes preceding and during the development of atopic diseases that could be leveraged for diagnostic, therapeutic, or prognostic purposes.

• DFG Programme: Collaborative Research Centres
• Subproject of: SFB 1340: In vivo Visualization of Extracellular Matrix Pathology „Matrix in Vision“
• Applicant Institution: shared FU Berlin and HU Berlin through:; Charité - Universitätsmedizin Berlin
• Project Heads: Professorin Dr. Sarah Hedtrich, since 7/2022; Professor Dr. Peter H. Seeberger; Professor Dr. Rudolf Tauber, until 6/2022